TG Therapeutics stock soars to 52-week high of $36.89

TG Therapeutics, Inc. (NASDAQ:TGTX) has reached a remarkable milestone, with its stock price soaring to a 52-week high of $36.89. The company, now valued at $5.2 billion, boasts impressive fundamentals with an 88.3% gross profit margin and strong revenue growth of 40.8% over the last twelve months. According to InvestingPro analysis, the stock appears to be trading above its Fair Value. This significant price level reflects a period of robust performance for the biopharmaceutical company, which has seen its shares more than double over the past year. The 1-year change data for TG Therapeutics is particularly impressive, showcasing a staggering 100.44% increase. This surge in stock value is indicative of investor confidence and the potential growth prospects for the company, as it continues to make strides in the development of novel treatments for B-cell malignancies and autoimmune diseases. InvestingPro subscribers can access 13 additional ProTips and a comprehensive Research Report that provides deep insights into TGTX’s valuation and growth prospects.

In other recent news, TG Therapeutics reported robust financial results for the fourth quarter of 2024, with earnings per share (EPS) of $0.15, exceeding the consensus estimate of $0.08. The company’s revenue for the quarter reached $108.2 million, surpassing the expected $97.66 million, marking a significant year-over-year growth. TG Therapeutics’ full-year revenue totaled $329.0 million, with $310.0 million attributed to net sales of Briumvi in the U.S. Additionally, Cantor Fitzgerald reiterated an Overweight rating on TG Therapeutics, citing potential upside for Briumvi’s 2025 revenue guidance of $525 million in the U.S. market. H.C. Wainwright also maintained a Buy rating with a $55 price target, reflecting confidence in the company’s financial outlook. The company’s strong cash position of $311.0 million at the end of 2024 supports ongoing operations and strategic initiatives. TG Therapeutics continues to focus on expanding Briumvi’s market presence, including launching in Europe through a partnership with Neuraxpharm. Recent developments suggest a promising financial trajectory for TG Therapeutics, with analysts optimistic about its future growth prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.